Registration

Developed under the direction and sponsorship of Lilly Medical Affairs and is intended for US healthcare professionals only.

High-Risk HR+, HER2- EBC: Patient ID & Tailoring Treatment for Community Oncologists

10/14/2025 • 2:00PM–3:00PM ET • 11:00AM–12:00PM PT

Join Medical Oncologist, Naomi Dempsey, of Baptist Health Cancer Center as she shares clinical data and insights for community oncologists in identifying and optimizing treatment for patients with high-risk HR+, HER2- Early Breast Cancer.

 

After viewing this webinar, community oncologists will be able to:

  • Explain the risk of disease recurrence and how this can guide treatment strategies
  • Assess which patients may benefit from the addition of a CDK4/6 inhibitor and formulate individualized treatment plans to optimize treatment selection
  • Formulate strategies to anticipate and manage adverse events associated with CDK4/6 inhibitors to support treatment adherence and maximize clinical outcomes

 

Agenda

  • Assessing risk to identify patients with HR+, HER2- EBC who are at a higher risk of recurrence
  • Implementing evidence in everyday clinical practice
  • Patient management strategies to maximize adherence and persistence

Register Below

By providing this information, you are agreeing that Matrix Medical Communications can contact you by email for purposes of administering the program for which you are registering.
(Required)

For more information about Lilly’s Privacy Practices, click here.

VV-OTHR-US-DEL-5192 08/2025 © 2025 Lilly USA, LLC. All rights reserved.